This will take effect January 20, 2014
Overview and Clinical Utility:
Effective January 20, 2014, PathGroup will insource Bioavailable Testosterone for Women and Children by LCMS. This test panel will include total testosterone by LCMS, Sex Hormone Binding Globulin (SHBG), free and bioavailable testosterone. This is an acceptable test in the evaluation of suspected hyperandrogenemia in women and children. The test panel is also acceptable for evaluating androgen deficiency in men.
Click Here to read more.